‘We’re responding to this threat’: University of Alberta works to help stop novel coronavirus – Calgary Herald

The University of Albertas Li Ka Shing Institute of Virology says a drug once used in an Ebola outbreak could fight the novel coronavirus.

Remdesivir will be tested against the virus, known as 2019-nCoV, at the institute in Edmonton. Although there are regulatory hurdles related to getting samples of the coronavirus into the country, lab work has already begun, said D. Lorne Tyrrell, founding director of the Li Ka Shing Institute of Virology.

The prospects for developing an antivirus that can be used in patients is very good, and it may happen in the next few weeks and be readily available some compounds that are already on the market for their viruses that might work (against) this virus, said Tyrrell.

The institute is aiming to raise up to half a million dollars in funding, including rapid response grants from the Canadian Institute of Health Research, to go towards work on the novel coronavirus, Tyrrell said.

No one at the institute specializes in coronavirus at the moment. That is going to change very quickly, said Tom Hobman, professor of medical microbiology and immunology at the university, who noted that experts on coronaviruses have been recruited.

Since it can take years to get a brand new drug to market, researchers at the institute hope to find a drug thats already been developed to fight the virus.

Remdesivir, one of the drugs they will test, was used in the emergency treatment of patients with Ebola virus infection in the Democratic Republic of the Congo. The drug has shown activity in animal models against the viral pathogens MERS and SARS, which are coronaviruses that are structurally similar to the novel coronavirus, and has been used on a small number of patients.

Since the outbreak of the new coronavirus, it was just logical to ask whether this drug will work against the new coronavirus. The good thing was that its been tested, with tons of pre-clinical data, as well as in very difficult clinical settings, said Matthias Gtte, chair of the department of medical microbiology and immunology.

We are interested, always, not in the entire virus, but in the little machines the enzymes that help the virus to propagate. As soon as you shut down the machine, you shut down the virus, and you have a drug, said Gtte. Now, the goal is to see if the mechanism works the same way against the novel coronavirus.

If youre trying to respond very quickly to an outbreak, you dont really have the luxury of time to develop something completely new, said Dave Evans, professor of medical microbiology and immunology.

The challenge with all drug development is making sure it works and is safe, so its a common approach to test drugs that are known to be safe on new viruses, said Evans.

Viruses change, and new viruses are always emerging, said Tyrrell.

Public health efforts to contain the novel coronavirus have been more challenging than in other outbreaks, including SARS, but the mortality rate is so far much lower, he said. There have been at least 40,000 confirmed cases of the novel coronavirus worldwide, and 910 deaths, according to The World Health Organizations latest numbers.

(The institute) has been designed to look after major outbreaks in the world like this, and I just want you to know that were responding to this threat, said Tyrrell.

lijohnson@postmedia.com

twitter.com/reportrix

Visit link:
'We're responding to this threat': University of Alberta works to help stop novel coronavirus - Calgary Herald

Moms Role to Protect From Childhood Allergic Sensitization – Physician’s Weekly

For most children, immunoglobulin E (IgE) sensitization to food and respiratory allergens begins during the first few years of life. However, maternal allergen-specific immunoglobulin G (IgG) is transferred to offspring during pregnancy, thereby possibly averting the evolution of allergic sensitization. Using IgE reactivity profiles from asymptomatic children in early life, it is possible to predict both the likelihood of a child developing symptoms later in life and the severity of those symptoms.

Several factors are known or suspected to have an impact on allergic sensitization in children, both in terms of protection from, and facilitation of, IgE formation, says Christian Lupinek, MD. From allergen-specific immunotherapy (AIT), allergen specific IgG antibodies that block IgE binding to the respective allergen are known to be beneficial, as they can reduce symptom load in an allergen-specific manner when the patient is exposed to an allergen.

For a study published in the Journal of Allergy and Clinical Immunology, Dr. Lupinek and colleagues analyzed IgG reactivity to more than 160 microarrayed allergens in mothers during pregnancy, cord blood samples, breast milk, and infants in the first years of life (6 months, 12 months, and 5 years), exploring whether maternal allergen-specific IgG could protect offspring from IgE sensitization. The samples allowed studying both mother-to-child transferring of allergen-specific IgG and the subsequent production of allergen-specific antibodies in the infant.

Children with IgE-sensitization also have higher IgG levels to the same respective allergen, says Dr. Lupinek. This demonstrates an obviously high general propensity in allergic subjects to mount an antibody response to harmless environmental antigens.

The study showed a high correlation among allergen-specific IgG reactivity profiles in mothers, cord blood, and breast milk. Maternal allergen-specific IgG remained for some children at 6 months. The data clearly visualize the decline of the passively transferred maternal allergen-specific IgG, which are present at birth but hardly remain at 6 months of age, says Dr. Lupinek.

Compared with nonsensitized children, those who were IgE sensitized against an allergen at age 5 showed monumentally elevated allergen-specific IgG levels at the same age. By contrast, mothers with elevated levels of IgG antibodies against an allergen in their blood exceeding 30 ISU-G had children without allergic IgE sensitizations toward that particular allergena finding consistent for all 164 tested allergens. In comparison, only children of mothers with lower allergen-specific IgG antibodies had IgE sensitization to allergens. This implies that induction or passive transfer of allergen-specific IgG in pregnant women may facilitate prevention of allergic sensitization in their offspring, says Dr. Lupinek.

When examining allergens against which children at age 5 were sensitized, the study team observed that to most allergens, no mother had mounted an IgG-response that exceeded a level of 30 ISU-G (Table). According to Dr. Lupinek, This implies that both the spectrum and the level of allergen-specific IgG spontaneously formed in mothers would not be sufficient to convey protection from sensitization to their offspring.

The study produces significant evidence that throughout pregnancy, elevated maternal allergen-specific IgG levels protect offspring from allergic sensitization, potentially providing new solutions in the prevention of allergic diseases. The initial post-natal months appear to be a key period for allergic sensitization, as levels of maternal IgG antibodies transferred to the child are already low at 6 months. The observation that the passive transfer of allergen-specific IgG from mother to child may protect the child from getting sensitized to the respective allergens allows us to develop new strategies for the prevention of allergic sensitization says Dr. Lupinek.

Allergen-specific immunotherapy (via vaccination) and passive immunization with IgG isolated from subjects with elevated levels of allergen-specific IgG can both increase the number of protective IgG antibodies in the plasma of pregnant women. AIT treatment of pregnant women can avert offsprings development of IgE sensitization against correlating allergens. In this context, says Dr. Lupinek, it seems to be relevant for the treatment to be effective that IgG-levels exceed a particular threshold (ie, 30 ISU-G).

Lupinek C, Hochwallner H, Johansson C, et al. Maternal allergen-specific IgG might protect the child against allergic sensitization. J Allergy Clin Immunol. 2019;144(2):536-548. Available at https://www.jacionline.org/article/S0091-6749(19)30106-X/fulltext.

Read more here:
Moms Role to Protect From Childhood Allergic Sensitization - Physician's Weekly

Sihuan Pharmaceutical and Hetero Labs Limited Reached A Framework Cooperation Agreement in Pharmaceutical Manufacturing Area – Yahoo Finance

HONG KONG, Feb. 12, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd.(HKEX: 0460) ("Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group and Hetero Labs Limited ("Hetero"), a company registered under the laws of India, reached a framework cooperation agreement (the "Cooperation") in the pharmaceutical manufacturing area after several rounds of discussion.

Under the terms of the framework cooperation agreement, the Cooperation includes research and development ("R&D"), product registration, technology transfer, raw materials supply and local manufacturing and commercialization of drugs in the fields of cardiovascular, cerebrovascular, neurology and anti-infectives including novel coronavirus (2019-nCoV), etc.

Backed by over 25 years of expertise in the pharmaceutical industry, Hetero is the world's leading producer of anti-retroviral drugs for the treatment of HIV/AIDS. Hetero caters about 40% of the identified HIV/AIDS patients globally through around 30 anti-retroviral products combinations. In addition, Hetero is growing as a reliable partner in the industry specializing in major therapeutic categories such as oncology, cardiovascular, neurology, hepatitis, nephrology, urology, diabetes, ophthalmology and immunology, etc., with around 300 products in the portfolio.

The signing of this framework cooperation agreement will achieve a win-win situation in which the two parties complement each other's strengths and jointly accelerate their development. On one hand, Hetero's anti-viral and anti-infection products will be introduced to China by Sihuan Phamaceutical which is equipped with standardized production capacity and strong marketing capabilities for local production and sales. This will also enrich the Group's R&D and product pipeline. On the other hand, Hetero will explore the great potential in the China market.

Dr. Che Fengsheng, Chairman and Executive Director of Sihuan Pharmaceutical said, "Based on the prevalence of the novel coronavirus infection pneumonia in China, both parties agreed to take the introduction, development and production of new coronavirus drugs as a priority issue, giving priority and contributing to China's fight against the pandemic ! "

-End -

About Hetero Labs Limited

Headquartered in Hyderabad, India, Hetero is one of India's leading generic pharmaceutical companies and one of the world's largest producers of anti-retroviral drugs for the treatment of HIV/AIDS. Backed by over 25 years of expertise in the pharmaceutical industry, Herero's strategic business areas spread across APIs, generics, biosimilars, custom pharmaceutical services and branded generics. Hetero is globally recognized for its strengths in research and development, manufacturing and commercialization of a wide range of products. Hetero caters about 40% of the identified HIV/AIDS patients globally through 30+ ARV products combinations . Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, audited and approved by stringent regulatory authorities like U.S. FDA, EU, TGA-Australia, MCC-South Africa and others. Hetero is growing as leader and reliable partner of choice in the major therapeutic categories such as HIV/AIDS, oncology, cardiovascular, neurology, hepatitis, nephrology, urology, diabetes, ophthalmology, hepatology and immunology etc., with over 300 products in the portfolio.

About Sihuan Pharmaceutical Holdings Group Ltd.

Founded in 2001, Sihuan Pharmaceutical is a pharmaceutical group with 21 subsidiaries and integrated R&D, production and marketing and sales capabilities. Because of the continuing efforts over the past decade, Sihuan Pharmaceutical has formed a R&D platform with over 1,000 researchers conducting more than 110 pharmaceutical research projects currently. More than 300 patents on innovative drugs were granted in China and over 80 are PCT patents, covering pipeline projects including important areas of diabetes, oncology, anti-infectives and non-alcoholic steatohepatitis etc.

SOURCE Sihuan Pharmaceutical Holdings Group Ltd.

Here is the original post:
Sihuan Pharmaceutical and Hetero Labs Limited Reached A Framework Cooperation Agreement in Pharmaceutical Manufacturing Area - Yahoo Finance

Immune Therapeutics Inc. Provides Updates and Guidance on Reverse Stock Split and Name Change – Yahoo Finance

Awaiting completion of FINRA approval process

Orlando, Florida--(Newsfile Corp. - February 11, 2020) - Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" "IMUN" or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases today announced an update on the pending 1000 to 1 reverse stock split and name change of Immune Therapeutics.

Immune Therapeutics originally submitted the reverse and name request for a corporate action to FINRA and paid the applicable fees on November 27, 2019. Since then, the company has responded to FINRA's requests for further information multiple times, and we continue in our efforts to work diligently and cooperatively with FINRA to process the reverse and name change. Please note that the Company has no control of the FINRA approval process and as such the timing of any decisions our not in the Company's control.

Michael K. Handley, CEO of Immune, said, "We are disappointed in the delay in processing the reverse and name change and remain fully committed to the restructuring and success of IMUN. I would personally like to thank all of our shareholders for their patience in this process. We realize this delay has eroded share value, and confidence however, based on the extensive review by FINRA, we are optimistic that their approval could be given soon, at which time we will certainly inform shareholders immediately. Immune would like to thank our shareholders for standing behind us, as we continue to work in your interests with a commitment to the reverse and merger with Aletheia as soon as possible."

ABOUT Immune Therapeutics Inc.

Immune Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of highly innovative therapies for use in oncology, immunology and anti-inflammatory disease. Immune Therapeutics is actively developing T-cell activation immunotherapies in combination with other drug candidates to achieve immunomodulation in patients with cancer, auto-immune disease and inflammatory diseases.

FORWARD LOOKING STATEMENTS

This release may contain forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all the matters and transactions considered by the Company may not proceed as contemplated, and by all other matters specified in the Company's filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company's filings with the Securities and Exchange Commission (www.sec.gov), including its recent periodic reports.

Contact:

Immune Therapeutics:Michael K. Handley(888) 613-8802 Ext. 100

http://www.immunetherapeutics.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/52312

More:
Immune Therapeutics Inc. Provides Updates and Guidance on Reverse Stock Split and Name Change - Yahoo Finance

Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in…

TORONTO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Eli Lilly and Company and Incyte announced that baricitinib met the primary endpoint in BREEZE-AD5, an investigational Phase 3, randomized, placebo-controlled study evaluating the safety and efficacy of baricitinib for the treatment of adult patients with moderate- to severe atopic dermatitis (AD). The primary endpoint was defined by the proportion of patients achieving at least a 75% or greater change from baseline in their Eczema Area and Severity Index (EASI) at Week 16.

"Atopic dermatitis is chronic skin condition which affects approximately one to three percent of adults worldwide.6 We appreciate the distressing impact this condition can have on a person's quality of life and the need for additional treatment options," says Dr. Doron Sagman, Vice President, R&D and Medical Affairs, Eli Lilly Canada. "We are pleased that baricitinib met the primary endpoint in the BREEZE-AD5 study, and we will continue to focus on patient-centered solutions."

BREEZE-AD5 is a multicenter, double-blind, randomized, placebo-controlled study designed for and conducted in North America and which evaluated the efficacy and safety of the 1-mg and 2-mg doses of baricitinib monotherapy for the treatment of adult patients with moderate- to severe AD. In this study, the 2-mg dose of baricitinib met the primary endpoint as defined by the proportion of participants achieving EASI75 at Week 16. Baricitinib also met key secondary endpoints including another measure of skin inflammation defined by clear or almost clear skin and at least 2 points improvement on the validated Investigator's Global Assessment for AD (vIGA 0 or 1 at Week 16), and it reduced itch severity.

P n.s. * P 0.05, and *** P 0.001 for baricitinib compared to placebo by analysis unadjusted for multiplicity. Non-responder imputation upon rescue with Topical corticosteroid (TCS). avIGA = validated Investigator's Global Assessment.

The safety profile in BREEZE-AD5 was consistent with the known safety findings of baricitinib in AD. The most common treatment-emergent adverse events (TEAEs) included upper respiratory tract infections, nasopharyngitis, and diarrhea. No venous thromboembolic events (VTEs) or deaths were reported in the trial. The full results from the BREEZE-AD5 study will be disclosed at future scientific venues and in peer-reviewed journals.

"These positive top-line results show that baricitinib could be an effective treatment option for patients living with moderate- to severe AD whose needs have remained unmet," says Dr. Gooderham, Dermatologist and study investigator.

About BREEZE-AD5BREEZE-AD5, a multicenter, double-blind, randomized, placebo-controlled, Phase 3 study in adult patients with moderate- to severe atopic dermatitis (AD). BREEZE-AD5, which was designed for and conducted in North America, evaluated the efficacy and safety of the 1-mg and 2-mg doses of baricitinib monotherapy for the treatment of adult patients with moderate to severe AD. The primary endpoint was defined by the proportion of participants achieving Eczema Area and Severity Index 75 (EASI75) at Week 16. BREEZE-AD5 completes the read out from the BREEZE development program, following the recent topline results from BREEZE-AD4. BREEZE-AD1, -AD2 and -AD7 results were disclosed in 2019.

About OLUMIANTOLUMIANT (baricitinib), in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of moderate- to severe rheumatoid arthritis (RA) in adult patients who have responded inadequately to one or more disease-modifying anti-rheumatic drugs (DMARDs). OLUMIANT can be used as a monotherapy in cases of intolerance to MTX.1

OLUMIANT is believed to interfere with the activity of an enzyme called Janus Kinase (JAK). Normally JAK enzymes help turn on your immune system when you need it. The immune system then causes swelling and tenderness. This is called inflammation. There are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2. JAK-dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoimmune diseases.1 OLUMIANT has greater inhibitory potency at JAK1, JAK2 and TYK2 relative to JAK3; however, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.

About Atopic DermatitisAtopic dermatitis (AD), or atopic eczema, is a chronic, relapsing skin disease characterized by intense itching, dry skin and inflammation that can be present on any part of the body.2 AD is a heterogeneous disease both clinically and biologically, but may be characterized by chronic baseline symptoms of itch, redness and skin damage that are often punctuated with episodic, sometimes unpredictable, flares or exacerbations.3,4 AD affects approximately 1-3% of adults worldwide.5

Moderate- to severe AD is characterized by intense itching, resulting in visibly damaged skin.6 Like other chronic inflammatory diseases, AD is immune-mediated and involves a complex interplay of immune cells and inflammatory cytokines.7

About Lilly in DermatologyBy following the science through unchartered territory, we continue Lilly's legacy of delivering innovative medicines that address unmet needs and have significant impacts on people's lives around the world. Skin-related diseases are more than skin deep. We understand the devastating impact this can have on people's lives. At Lilly, we are relentlessly pursuing a robust dermatology pipeline to provide innovative, patient-centered solutions so patients with skin-related diseases can aspire to live life without limitations.

About Eli Lilly CanadaEli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by Colonel Eli Lilly, who was committed to creating high quality medicines that meet people's needs, and today we remain true to that mission in all our work. Lilly employees work to discover and bring life-changing medicines to people who need them, improve the understanding and management of disease, and contribute to our communities through philanthropy and volunteerism.

Eli Lilly Canada was established in 1938, the result of a research collaboration with scientists at the University of Toronto, which eventually produced the world's first commercially-available insulin. Our work focuses on oncology, diabetes, autoimmunity, neurodegeneration, and pain. To learn more about Lilly Canada, please visit us at http://www.lilly.ca.

For our perspective on issues in healthcare and innovation, follow us on twitter @LillyPadCA

About IncyteIncyteis aWilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information onIncyte, please visit Incyte.com and follow @Incyte.

Media Contact: Samira RehmanRehman_Samira@lilly.com 647-617-1994

REFERENCES

1 OLUMIANT Product Monograph2 Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. The Journal of Allergy and Clinical Immunology. 2006;118: 226-32.3 Thijs JL, Strickland I, Bruijnzeel-Koomen C, et. al. Moving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis. The Journal of Allergy and Clinical Immunology. 2017.4 Langan SM, Thomas KS, Williams HC. What is meant by "flare" in atopic dermatitis? A systematic review and proposal. Arch Dermatol. 2006;142:1190-1196.5 Nutten S. Atopic dermatitis: global epidemiology and risk factors. Annals of Nutrition and Metabolism. 2015;66(suppl 1): 8-16.6 Yosipovitch G, Papoiu AD. What causes itch in atopic dermatitis? Current Allergy and Asthma Reports. 2008;8:306-311.7 Weidinger, S, Novak, N. Atopic dermatitis. The Lancet Volume 387. 2016;10023:1109-1122.

Read the original here:
Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in...

IONpath Launches Research Services Offering Multiplexed Tissue Analysis to Empower Pharmaceutical Discovery and Development Programs – BioSpace

MENLO PARK, Calif., Feb. 11, 2020 /PRNewswire/ -- Ionpath Inc., today announces the launch of a dedicated service business providing access to their proprietary MIBIscope multiplexed imaging platform and its team of experts to support pharmaceutical and biotechnology companies working in immuno-oncology.

IONpath has previously provided custom research services to leading academic and pharmaceutical organizations as part of an Early Access Program. Now the company has formalized its intentions to become a partner of choice to those interrogating the tumor microenvironment to understand therapeutic mechanism of action and identify responder populations.

"We started this company because we love doing great science and working with great scientists," said Harris Fienberg, chief executive officer and co-founder, IONpath. "Our team is incredibly excited to enable the next generation of immunotherapy development on a massive scale."

Based in their global headquarters in Silicon Valley and serving clients from around the world, an expert team of engineers, pathologists and data scientists are leveraging the proprietary MIBIscope platform to help solve the most complex problems in immuno-oncology. The MIBIscope can simultaneously image forty or more individual proteins on a single slide with the reproducibility needed for large clinical studies. IONpath is building the capacity to stain, image and analyze over 15,000 highly multiplexed slides a year by the end of 2020. The company hopes to unlock valuable data about co-expression levels, proximity of cell populations and correlations to outcomes observed in patients to meaningfully contribute to the development of immunotherapies for partners across industry and academia.

If you or your company would be interested in learning more about what Research Services can do for your program, please contact us at research@ionpath.comto talk to our expert team or request a quote.

About IONpath, Inc.IONpath, Inc. is revolutionizing tissue imaging to accelerate medical discovery and improve human health. The company's MIBIscope System, which utilizes Multiplexed Ion Beam Imaging (MIBI) technology, represents a transformative step in tissue imaging by simultaneously multiplexing 40+ markers with single cell resolution. Leading research institutes and biotech and pharmaceutical companies are using the MIBIscope in immuno-oncology, immunology and neuroscience research where high-fidelity multiplexed imaging data is needed. In addition to the MIBIscope System IONpath empowers the research and development initiatives of academic, biotech and pharmaceutical partners through IONpath Research Services.

Visit http://www.ionpath.com to find out more.

Contact:Terri Hnatyszyn305-803-0824media@ionpath.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/ionpath-launches-research-services-offering-multiplexed-tissue-analysis-to-empower-pharmaceutical-discovery-and-development-programs-301003116.html

SOURCE IONpath, Inc.

Go here to see the original:
IONpath Launches Research Services Offering Multiplexed Tissue Analysis to Empower Pharmaceutical Discovery and Development Programs - BioSpace

Neuroscience study finds evidence that meditation increases the entropy of brainwaves – PsyPost

New research suggests that the brain displays a similar pattern of chaotic activity during meditation as it does during the psychedelic experience. The findings, published in the journal Neuroscience, indicate that meditation is associated with increased brain entropy.

We are currently witnessing a major psychedelic renaissance, both in science and society. Psychedelics are being reconsidered as comparatively safe tools to investigate the relationship between brain, mind and consciousness, as well as promising clinical alternatives to treat certain psychiatric disorders, such as depression, explained study author Enzo Tagliazucchi a professor at the University of Buenos Aires and director of the Computational Cognitive Neuroscience Lab.

I became interested in certain overlaps between the phenomenology (i.e. what it feels like) of some meditation traditions and the psychedelic state. For instance, both states have been consistently linked to a collapse of self-boundaries and a merging of the subjective and objective sides of reality.

My colleague Robin Carhart-Harris, one of the leading figures of the psychedelic renaissance, has put forward a theory of the psychedelic state as a brain state of increased entropy, and I became interested in finding out whether meditation could also be associated with increases in the entropy of brain activity.

Brain entropy describes the randomness and predictability of brain activity. Tagliazucchi and Carhart-Harris were previously involved in research which found that people had higher brain entropy meaning a larger range of potential brain states under the influence of the psychedelic drug psilocybin.

Other research has found that higher entropy in several key brain areas is associated with higher intelligence. But heightened brain entropy has also been observed in patients with schizophrenia.

In his new study, Tagliazucchi and his colleagues recorded participants brainwaves to calculate their brain entropy during meditation. Electrical brain activity and oscillation patterns were measured by electroencephalogram in 27 Himalaya Yoga meditators, 20 Vipassana meditators, 27 Isha Yoga meditators, and 30 individuals with no meditation experience.

The researchers found that Vipassana meditation resulted in the highest entropy increases, with the most salient increases occurring in alpha and gamma brainwaves.

In spite of not feeling at all like brain activity, your conscious experience is the result of processes that happen in the brain, and because of this there has to be a correspondence between what happens physically in the brain and how that feels in your first-person point of view, Tagliazucchi told PsyPost.

The acute effects of psychedelics and some meditative practices both lead to states departing from ordinary conscious wakefulness, and are experienced subjectively as richer in information and capable of sustaining an ample repertoire of contents. Because of this, we hypothesized that meditation would be associated with increased information content (in other words, increased entropy) of brain activity recordings, which was confirmed in the study.

Future research could use other tools such as functional magnetic resonance imaging or magnetoencephalography to examine brain entropy during meditation.

We need to replicate this result using other techniques to measure brain activity. We also need to probe the conscious experience of the subjects during or immediately after their meditation practice to verify whether time to time changes in entropy correspond to the fluctuating nature of their subjective experience, Tagliazucchi explained.

The study, Meditation Increases the Entropy of Brain Oscillatory Activity, was authored by Roco Martnez Vivot, Carla Pallavicinia, Federico Zamberlan, Daniel Vigo, and Enzo Tagliazucchi.

See the original post here:
Neuroscience study finds evidence that meditation increases the entropy of brainwaves - PsyPost

The Neuroscience of Friendship – The American Prospect

The Open Mindexplores the world of ideas across politics, media, science, technology, and the arts.The American Prospectis republishing this excerpt.

Alexander Heffner: We need more friends in our lives today in this digital environment.

Lydia Denworth: We do. As a science writer I mostly cover the brain. What neuroscience is mainly interested in these days is mapping connections in the brain and inside the brain. I went to a meeting about social neuroscience, which is a sort of newer field within neuroscience, that is about mapping connections in and outside of the brain, this kind of web of connections that we have with other people. I sat there at this meeting listening to them talking about all these elements of social behavior and what it does in the brain.

I was right at that moment sort of wedged in between a parent with Alzheimers disease and teenagers. So I was very buffeted day in day out by other peoples emotions and ups and downs. It made me think about the ways that people in our lives affect us, even our biology, the way they make your pulse pound and your adrenaline spike.

But then I also thought about here I am losing my parents and my kids are growing up and out: I better make sure Ive got my friends. Thats one of the big topics that social neuroscience gets intothats really how I came to it. It was that kind of confluence of my personal life and the work I was already doing.

Heffner: You are giving rebirth to this science in the book and youre acknowledging that friendship revitalizes us.

Denworth: Right. The newest part of the science is the biology, this question of how is it that a social relationship, which is not like food that you actually put in your body or exercise where youre moving your muscles and you can understand why going for a run might affect your blood pressure. But why is it that a conversation with a good friend sort of gets inside your body and changes the way your body works? I mean it literally affects your blood pressure, your sleep, your stress responses, your immune system, all of those things.

Friendship for a long time was not studied seriously by biologists, anyway, because its very hard to measure. Its hard to defineand science is all about measurement and definition. You need to know what it is youre trying to measure in order to sort of make a statement about it. While friendship in human society has a lot of cultural aspects to it, and its not entirely cultural and thats the way people imagined it for a long time. C.S. Lewis, the famous writer, he said, you know, friendship has no survival value, but it gives value to survival. In people, but also in other species, those with the strongest social bonds live longest, have the most reproductive success, which is the evolutionary measure that you want.

Heffner: Thats one thing that really struck me about the book and the subject because we are in this climate of increasing domestic terrorism, and, of course, lone wolf attacks where there are stories after stories of assassins who have massacred people because they were not, they didnt have friends. So we need to understand the science of how we can relate socially to rebuild capital, social capital.

Denworth: It is so distressing to see these people who are so unconnected and or they think theyre connecting online with people who think like they do. But that is so different from what real true friendship is. But, you know, were not stupid. We know that our Facebook friend that we actually never see, you know, havent seen in years is not the same thing as your best friend that you call when something good or bad happens in your life. I am sure that kids who really feel connected are just much less likely to go down that path.

We need to understand, with children anyway, often we are pushing them to accomplish things and they seem obsessed with their friends. And as a parent we sometimes say, well, okay, your friends are great, but you know, you need to do this. Thats not untrue at times, but I do think its really important to stop and check ourselves and say, wait a minute, are we making sure that they are building relationships that they need?

Heffner: You said two things that interest me greatly. One is about feeling connected and the other is about friendships outside of the family.

Denworth: This new science of friendship both blurs the lines between family and friends and also helps us to try to understand the differences. So, the word friend is qualitative, right, its, its about a relationship and emotion. And it tells you if I call someone a friend, it tells you something about how I feel about them. It should. And if I, you know, refer to my husband or my son or my siblings, that those words are, theyre categorical. They tell you how were connected.

But they dont actually tell you anything about the quality of our relationship, which is why when people like to say that their spouse is their best friend but they do that specifically to tell you that their marriage is good.

Heffner: Qualitatively, right?

Denworth: Qualitatively, exactly. To add to what you know about that marriage. And the truth is that marriage can, your spouse can be your best friend, but, also not, sadly in a bunch of cases. And, and in fact it for a long time we didnt aspire to have our spouse be our best friend, you know, so but one of the things that is really important is quality. Thats why friendship can be a template for all other relationships because when you think of your closest friends, you really think about the positive, the way that you treat each other positively.

Heffner: Unfortunately, there are those who would feel connected by virtue of tribe only. When I mentioned the rise of bigotry and new racism, the new Jim Crow in this country, folks unfortunately can feel connected on chat rooms and then go out and massacre people because theyre not their same race or from the same country theyre from.

Denworth: The work on the neuroscience of empathy speaks to what youre talking about here. Which is that first of all, we understand now that theyre there in many ways theres positive elements of empathy. When we think of empathy, we think of it as a good thing, but it also carries with it that kind of us/them that, that, in-group and out-group sort of element and, and you can see it. What I hope is that understanding how our brains work and that we do bring implicit bias, all of us into the world. Theres a lot of research that shows that then you have to be aware of it and then you have to work to counter it a little bit.

Heffner: In this political climate there, people often riff on the strength of their friendship and whether or not politics can get in the way. I was wondering if thats something that you grappled with, the fact that sometimes you need a base level of values.

Denworth: Of values, you do. In fact, I think one of the really interesting things is that worldview is one of the things that most draws us together with, with someone else.

Heffner: Where is the research going right now?

Denworth: The neuroscience really intrigues me. Theyre trying to look at the brains of two people as they interact and essentially capture friendship while its happening. The idea is, is there some place that your brains go when youre interacting with a friend that they wouldnt get to on their own? And can we see it? Can we see it in a brain scanner? What we do know is that and just in the last year or two, we know that the way your brain processes the world is more similar to the way your friends brain processes the world than it is to people to whom youre not as close.

The question is, do you and your friend process the world the same way and thats part of what draws you together. I mean, you cant know it; you cant look at someone and say, I see how you are, you know, auditory cortex is operating but you, but you might end up being drawn to each other or do you become more similar as you are together? We dont know the answer yet. Theyre working on that, but its probably a little of both.

See the article here:
The Neuroscience of Friendship - The American Prospect

Emotional Analytics Industry to Exhibit a CAGR of 15.6% During 2019-2027 – Biometrics & Neuroscience Technologies are Leading the Market -…

DUBLIN, Feb. 11, 2020 /PRNewswire/ -- The "Global Emotional Analytics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2019 To 2027" report has been added to ResearchAndMarkets.com's offering.

The global emotional analytics market is expected to expand at a CAGR of 15.6% during the forecast period from 2019 to 2027.

The rising adoption of Big Data analytics and artificial intelligence (AI) are a few of the major factors driving the growth of the emotional analytics market. Emotional Analytics has grown its importance in industries including call centers, sales, and marketing among others. It is often used in call centers as a standalone application or in a customer relationship management system, which uses audio mining techniques and correlation engines to monitor caller's word and emotions.

Based on technology, Biometrics and neuroscience segment is leading the emotional analytics market as it enhances the safeguarding of the business operations. With biometric technology becoming more widespread, enterprises and governments are adopting the technology to create a secure, and fast experience for employees when logging into workplace networks and applications. The rapid adoption and application of emotional analytics are expected to propel the growth of the market.

Based on geography, the emotional analytics market is dominated by the North America region owing to its dominance to the rapid adoption of artificial intelligence technology and Big Data analytics. North America is trailed by Europe as numerous end-user industry verticals such as defense and security agencies and government among others are rapidly adopting emotional analytics software. The increasing adoption of facial biometrics within various industries such as banking, finance, sales, and marketing among others is embarking the growth to a large extent.

Widespread application of Big Data and artificial intelligence are creating broader opportunities for emotional analytics developers. Technology companies involved in developing emotional analytics software are aggressively focusing on the development of advanced emotion detection APIs, facial biometric tools and camera-based analytics platforms among others. For instance, Beyond Verbal an Israeli start-up has developed an engine that measures a person's emotional state based on their vocal intonations. This engine is being used in various call centers and they have seen tremendous growth in their sales after the software's deployment.

Some of the leading manufacturers/developers profiled in the study include Google, Inc., Apple, Inc., Facebook, Inc., Microsoft Corporation, IBM Corporation, Kairos AR, Inc., Affectiva Inc., Beyond Verbal, Eyris (Emovu), iMotions A/S, sensation.io, RealComm Global LLC, Neuromore Inc., Lightspeed LLC, Retinad Virtual Reality Inc. among others.

Key Topics Covered

1. Preface

2. Executive Summary2.1. Global Emotional Analytics Market Snapshot2.2. Global Emotional Analytics Market, by Technology, 2018 (US$ Mn)2.3. Global Emotional Analytics Market, by Application, 2018 (US$ Mn)2.4. Global Emotional Analytics Market, by Type, 2018 (US$ Mn)2.5. Global Emotional Analytics Market, by Solutions, 2018 (US$ Mn)2.6. Global Emotional Analytics Market, by End-use vertical, 2018 (US$ Mn)2.7. Global Emotional Analytics Market, by Geography, 2018 (US$ Mn)

3. Global Emotional Analytics Market Analysis3.1. Global Emotional Analytics Market Overview3.2. Market Inclination Insights3.2.1. Recent Trends3.2.2. Future Outlook3.3. Market Dynamics3.3.1. Market Drivers3.3.2. Market Challenges3.4. Attractive Investment Proposition, by Geography, 20183.5. Competitive Landscape3.5.1. Market Positioning of the Leading Manufacturers3.5.2. Major Strategies Adopted

4. Global Emotional Analytics Market Value, by Technology, 2018 - 2027 (US$ Mn)4.1. Comparative Analysis4.1.1. Emotional Analytics Market Value, by Application, 2018 & 2027 (Value %)4.2. Artificial Intelligence4.3. Biometrics and Neuroscience4.4. 3D Modelling4.5. Pattern Recognition4.6. Records management4.7. Others (Facial Recognition)

5. Global Emotional Analytics Market Value, by Application , 2018 - 2027 (US$ Mn)5.1. Comparative Analysis5.1.1. Emotional Analytics Market Value, by Application, 2018 & 2027 (Value %)5.2. Customer Experience Management5.3. Competitive Intelligence5.4. Sales and Marketing Management

6. Global Emotional Analytics Market Value, by Type, 2018 - 2027 (US$ Mn)6.1. Comparative Analysis6.1.1. Emotional Analytics Market Value, by Solutions, 2018 & 2027 (Value %)6.2. Text6.3. Facial6.4. Speech6.5. Video Analytics

7. Global Emotional Analytics Market Value, by Solutions, 2018 - 2027 (US$ Mn)7.1. API & SDK7.2. Mobile and Web Application7.3. Cloud

8. Global Emotional Analytics Market Value, by End-use vertical, 2018 - 2027 (US$ Mn)8.1. Comparative Analysis8.1.1. Emotional Analytics Market Value, by End-use vertical, 2018 & 2027 (Value %)8.2. Enterprises8.3. Defense and Security agencies8.4. Commercial8.5. Industrial8.6. Others (personal users)

9. North America Emotional Analytics Market Analysis, 2018 - 2027 (US$ Mn)

10. Europe Emotional Analytics Market Analysis, 2018 - 2027 (US$ Mn)

11. Asia-Pacific Emotional Analytics Market Analysis, 2018 - 2027 (US$ Mn)

12. Rest of World Emotional Analytics Market Analysis, 2018 - 2027 (US$ Mn)

13. Company Profiles13.1. Google, Inc.13.2. Apple, Inc.13.3. Facebook, Inc.13.4. Microsoft Corporation13.5. IBM Corporation13.6. Kairos AR Inc.13.7. Affectiva Inc.13.8. Beyond Verbal13.9. Eyris (Emovu)13.10. iMotions A/S13.11. sensation.io13.12. RealComm Global LLC13.13. Neuromore Inc.13.14. Lightspeed LLC13.15. Retinad Virtual Reality Inc.

For more information about this report visit https://www.researchandmarkets.com/r/w9ka7x

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Original post:
Emotional Analytics Industry to Exhibit a CAGR of 15.6% During 2019-2027 - Biometrics & Neuroscience Technologies are Leading the Market -...

CCMB teams follow-up discovery finds mention in ACS Neuroscience journal – The Hindu

In a follow-up discovery published in the American Chemical Society journal, ACS Chemical Neuroscience, Professor Amitabha Chattopadhyays group from the CSIR-Centre for Cellular and Molecular Biology (CCMB) here has now shown that modulating the levels of cholesterol - an important lipid in the cell membrane - could change serotonin1A receptor's internal mechanism.

Serotonin1A receptor is one such important drug target in neuropsychiatric disorders such as anxiety and depression. Its function is regulated inside the cell through a process called endocytosis - a key event in the therapeutic action of several drugs, according to a release.

Cells in the human body body communicate with their surroundings through tiny nano-machines called G Protein-Coupled Receptors (GPCRs) present in its outermost membrane which are major drug targets in almost all clinical areas.

Prof. Chattopadhyays team had previously shown that the serotonin1A receptor regulates through specialized regions of the cell membrane, called clathrin-coated pits, and later recycles into the cell membrane.

When CCMB researchers treated cells with statin - the best-selling cholesterol lowering drug in the market - they observed that the serotonin1A receptor, instead of using its regular clathrin-coated pits, used alternate regions called caveolae. We observed that this switch in the mechanism of internal regulation reverted to clathrin-coated pits when we put back cholesterol in cells without statin treatment, said G. Aditya Kumar, a Ph.D. student and first author of the paper.

Experiments from the team also revealed that receptors that usually recycle back to the cell membrane in normal conditions started getting degraded inside cells when they were treated with statin.

Anti-depressant drugs, termed selective serotonin reuptake inhibitors (SSRIs), target the endocytosis of serotonin1A receptor as their mechanism of action.

These results show cholesterol modulates cells internal mechanism and could provide novel insights into improved therapeutic activity of antidepressant drugs when administered in combination with statins, said Prof. Chattopadhyay.

These studies from CCMB are especially relevant in the Indian context since the National Mental Health Survey (2015-16) reported that more than five per cent of the adult Indian population suffers from depression.

You have reached your limit for free articles this month.

Register to The Hindu for free and get unlimited access for 30 days.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Link:
CCMB teams follow-up discovery finds mention in ACS Neuroscience journal - The Hindu